A phase 1/2 open-label, multicenter, first-in-human study of the safety, tolerability, pharmacokinetics, and antitumor activity of BH-30643 in adult subjects with locally advanced or metastatic NSCLC ...

New trial data in melanoma and early findings in head and neck cancer are advancing individualized vaccines, while questions ...

LCMC LEADER neoadjuvant screening trial: LCMC4 evaluation of actionable drivers in early-stage lung cancers. Background: Anti–PD-(L)1-directed therapy following radiotherapy or following concurrent ...

Following the approval of the additional indication for pembrolizumab (brand name: Keytruda) for platinum-resistant recurrent ...

In this extended follow-up from the phase 3 KEYNOTE-826 trial, researchers reported on 5-year outcomes of pembrolizumab and chemotherapy in cervical cancer.

Immune checkpoints are regulators of the immune system. The interaction between PD-L1 (red molecule) on the surface of a cancer cell (red) and the immune checkpoint PD-1 (blue molecule) on a T-cell ...

R/M immune checkpoint inhibitor naïve patients Company continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing partnership strategy for PDS0101 PRINCETON, N.J., Sept. 22, ...

Please provide your email address to receive an email when new articles are posted on . Adjuvant pembrolizumab plus belzutifan significantly improved DFS compared with pembrolizumab monotherapy in ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved KEYTRUDA QLEX™ (pembrolizumab and ...

The survey period covers 168 hours from 10:00 on September 16, 2026, to 10:00 on September 23, 2026 (JST).This week, Japan saw the successive approval of a ctDNA test for detecting minimal residual ...